| | | | | | | |

Compound in Pacific Sea Squirt Kills Mesothelioma Cells

930351131_55de272264_zThere is new evidence that compounds isolated from a sea squirt found in the waters off of the Indonesian coast may hold the key to fighting mesothelioma and several other malignancies.

The potential anticancer and antimicrobial properties are found in polysulfur aromatic alkaloids found in a Pacific sea squirt whose scientific name is Lissoclinum badium.

In a new article in the Journal of Natural Products, researchers from Japan’s Tohoku Medical and Pharmaceutical University and Sam Ratulangi University in Indonesia say they’ve discovered how these compounds may kill certain kinds of cancer cells, including pleural mesothelioma.

Their research could open the door to formal testing and, eventually, new and more effective mesothelioma treatments and longer survival.

Anticancer Properties of Marine Life

Cancer drug discovery research based on marine organisms from Eastern Indonesia is not a new phenomenon.

In 2015, researcher Yosmina Tapilatu of the Deep Sea Research Center at the Indonesian Institute of Sciences published an extensive paper on the status of such research dating back to the 1990s.

The paper includes a list of marine organisms from sponges and corals to seaweeds and sea squirts like Lissoclinum badium that produce compounds with anticancer properties. Alkaloids like the compound used on mesothelioma cells in the new study are among the most common pharmacologically active compounds found in these organisms.

Testing the Sea Squirt Compound

To evaluate the potential of these alkaloids to combat cancer, the research team first tested them on different cancer cell lines in the laboratory including colon cancer cells, cervical cancer cells, breast cancer cells and pleural mesothelioma cells.

They found that one alkaloid in particular – Lissoclibadin 1 – was the most toxic to all of the cells, including the mesothelioma cells. The compound induced mesothelioma cell death (apoptosis) by reactivating a cell-death signaling pathway that is often turned off in cancer cells.

With the promise of the compounds validated in vitro, the team moved on to testing in live mice that had been infected with colon cancer.

“In vivo studies demonstrated that [Lissoclibadin 1] suppressed tumor growth in nude mice carrying HCT-15 cells without significant secondary adverse effects,” states the paper’s first author Takeo Tatsuta with Tohoku University.

Hopeful News for Mesothelioma Patients

The news that these compounds killed cancer cells without causing serious side effects is especially exciting for mesothelioma patients since current treatments including chemotherapy, surgery, and radiation often cause complications and are only marginally effective at extending mesothelioma survival.

The report concludes that Lissoclibadin 1 “has potential as a chemotherapeutic candidate” for pleural mesothelioma and other cancers and should be investigated further in preclinical trials.

Currently, Alimta (pemetrexed) is the only chemotherapeutic agent approved by the FDA specifically for the treatment of mesothelioma.

Sources:

Tatsuta, T, et al, “Lissoclibadin 1, a Polysulfur Aromatic Alkaloid from the Indonesian Ascidian Lissoclinum cf. badium, Induces Caspase-Dependent Apoptosis in Human Colon Cancer Cells and Suppresses Tumor Growth in Nude Mice”, February 9, 2017, Journal of Natural Products, Epub ahead of print

Tapilatu, Yosmina, “Status of Drug Discovery Research Based on Marine Organisms from Eastern Indonesia”, March 18, 2015, Procedia Chemistry, pp. 484-492

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…